熱門資訊> 正文
ARK Investment buys 560K shares of Intellia Therapeutics
2025-08-19 17:23
- Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA).
- The stock has a Seeking Alpha quant rating of Hold, with the factor grades given to momentum.
- SA Investing Group Leader Edmund Ingham recently upgraded his rating to Buy, citing its lead gene-editing therapies, Lonvo-z and Nex-z, potential with 'one and done' treatment and strong early efficacy and safety data. ''Despite risks, I see NTLA stock as a compelling long-term Buy with triple-digit percentage upside if efficacy and safety are confirmed in late-stage trials." he wrote.
- The stock price traded ~1% higher to $10.83 on Monday during after-market hours of trading.
More on Intellia Therapeutics
- Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
- Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
- With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
- Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates
- Intellia Therapeutics Q2 2025 Earnings Preview
推薦文章
美股機會日報 | 通脹超預期！美國12月核心PCE物價指數年率創近一年新高；Applovin盤前漲超4%，傳OpenAI擬與其合作實現商業化
美股機會日報 | 估值8500億美元！傳OpenAI最新融資規模將破千億美元；黃仁勛稱將發佈幾款世界前所未見的新芯片
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
